Did the FDA Just Threaten Glaxo's Future?

Did the FDA Just Threaten Glaxo's Future?

This episode of The Motley Fool's Market Checkup drills down on the day's hottest headlines and plays a game of investing chicken with the world's biggest biotech. Market Checkup gives a full examination of the potential new generic threat to a big-time blockbuster drug and looks at a study questioning the benefits of robotic surgery.

In this video, health-care analysts David Williamson and Max Macaluso discuss the FDA decision to lower the barrier to entry for Advair generics. The drug is critically important for GlaxoSmithKline. Watch and find out why Glaxo hadn't been anticipating generic competition for a few more years, what next generation COPD drugs it is counting on, and if this bad news combined with the $490 million Chinese bribery allegations makes the stock a stay-away.

Stick with dividend stocks
One of the best parts of owning big pharma stocks is their attractive dividends, but smart investors know the importance of diversifying -- seeking high-yielding stocks from multiple industries. The Motley Fool's special free report "Secure Your Future With 9 Rock-Solid Dividend Stocks" outlines the Fool's favorite dependable dividend-paying stocks across all sectors. Grab your free copy by clicking here.

Follow David on Twitter @MotleyDavid.

The article Did the FDA Just Threaten Glaxo's Future? originally appeared on Fool.com.

David Williamson owns shares of Novartis. Max Macaluso, Ph.D. has no position in any stocks mentioned, and neither does The Motley Fool. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.